Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19901)	5/4/1998 1:19:00 AM
From: B.D.	Read Replies (3) \| Respond to of 32384

Henry, An interesting article appeared tonight on the AP Newswire. Here's the story as made available from the NYT website: nytimes.com The article is about Harvard's Dr. Judah Folkman who's working on drugs called "angiostatin" and "endostatin" that block blood flow to tumors. Apparently the research on mice has been extremely promising. The article ends with a quote from a Nobel laureate claiming Folkman will have the cure for cancer within 2 years. How do LGND's drugs fit in with or compare to angiostatin and endostatin? Do they complement them? Are they better? Also, there's a company called EntreMed (Nasdaq: ENMD) that apparently has some rights to endostatin. Entremed had a late 1996 press release about it: entremed.com I was wondering how this all might affect/benefit/compete with Ligand?